A5056946123- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Immunodeficiency and Autoimmune Disorders
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Monoclonal and Polyclonal Antibodies Research
- Advanced Breast Cancer Therapies
- Multiple Myeloma Research and Treatments
- Galectins and Cancer Biology
- T-cell and Retrovirus Studies
- Sarcoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Multiple and Secondary Primary Cancers
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Glycosylation and Glycoproteins Research
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Histone Deacetylase Inhibitors Research
- Cutaneous lymphoproliferative disorders research
- PI3K/AKT/mTOR signaling in cancer
Emory University
2004-2024
Cornell University
2015-2024
Fred Hutch Cancer Center
2013-2024
Sylvester Comprehensive Cancer Center
2024
City Of Hope National Medical Center
2024
Moffitt Cancer Center
2024
Prisma Health
2024
City of Hope
2024
The University of Texas Health Science Center at San Antonio
2024
Emory University Hospital
2021-2023
The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes survival proliferation CLL cells.We conducted a phase 1b-2 multicenter study to assess safety, efficacy, pharmacokinetics, pharmacodynamics ibrutinib (PCI-32765), first-in-class, oral covalent inhibitor BTK designed for B-cell cancers, patients...
Bruton's tyrosine kinase (BTK) is a mediator of the B-cell–receptor signaling pathway implicated in pathogenesis B-cell cancers. In phase 1 study, ibrutinib, BTK inhibitor, showed antitumor activity several types non-Hodgkin's lymphoma, including mantle-cell lymphoma.
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and effective in chronic lymphocytic leukemia (CLL). Resistance to inhibitors resistance associated with BTK inhibition have not been characterized. Although only a small proportion patients had relapse during ibrutinib therapy, understanding mechanisms important. We evaluated relapsed disease identify mutations that may mediate resistance.
Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth survival of malignant B lymphocytes. In a phase 1 study, idelalisib, an orally active selective PI3Kδ inhibitor, showed antitumor activity in patients with previously treated indolent non-Hodgkin's lymphomas.
<h3>Importance</h3> The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy this drug and outcomes following discontinuation have not been evaluated outside of clinical trials relatively short follow-up. <h3>Objective</h3> To determine features associated outcomes. <h3>Design, Setting, Participants</h3> A total 308 participating 4 sequential at Ohio State University Comprehensive Cancer Center...
Purpose Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift therapy, and relapse been uncommon current follow-up. Acquired mutations BTK PLCG2 can cause relapse, but data regarding the prevalence natural history these are limited. Patients Methods accrued four sequential studies were included analyses. Deep sequencing for was performed retrospectively on patients who experienced prospectively screening population....
Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, prednisone (R-CHOP) as frontline therapy for diffuse large B-cell lymphoma.Patients received six cycles of DA-EPOCH-R or R-CHOP. The primary objective was progression-free survival (PFS); secondary clinical objectives included response rate, overall (OS), safety.Between 2005 2013, 524...
Purpose Although ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) has been established as the standard of care in patients with advanced Hodgkin lymphoma, newer regimens have investigated, which appeared superior early phase II studies. Our aim was to determine if failure-free survival treated Stanford V regimen compared ABVD. Patients Methods The Eastern Cooperative Oncology Group, along Cancer Leukemia Group B, Southwest Canadian NCIC Clinical Trials conducted this randomized...
Abstract Purpose: The safety and efficacy of ibrutinib, a once-daily Bruton's tyrosine kinase (BTK) inhibitor, in chronic lymphocytic leukemia/small lymphoma (CLL/SLL) was demonstrated this phase Ib/II study. Extended follow-up up to 8 years is described, representing the longest for single-agent or any BTK date. Patients Methods: Phase PCYC-1102 (NCT01105247) extension study PCYC-1103 (NCT01109069) included patients receiving ibrutinib first-line relapsed/refractory CLL/SLL. Results:...
BackgroundIncorporating brentuximab vedotin into the treatment of advanced-stage classic Hodgkin's lymphoma improves outcomes in adult and pediatric patients. However, increases toxic effects adults, more than half patients who receive drug undergo consolidative radiation, relapse remains a challenge. Programmed death 1 blockade is effective lymphoma, including preliminary studies involving previously untreated patients.MethodsWe conducted phase 3, multicenter, open-label, randomized trial...
Patients with chronic lymphocytic leukemia (CLL) high-risk genomic features achieve poor outcomes traditional therapies. A phase I study of a pharmacokinetically derived schedule flavopiridol suggested promising activity in CLL, irrespective features. Given the relevance these findings to treating genetically prospective confirmatory was initiated.
PURPOSE Mantle-cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin's with a poor prognosis. We explored the feasibility, safety, and effectiveness of immunochemotherapy treatment program that included autologous stem-cell transplantation (ASCT) for patients up to age 69 years newly diagnosed MCL. PATIENTS AND METHODS The primary end point was 2-year progression-free survival (PFS). A successful trial would yield PFS at least 50% event rate (early progression plus nonrelapse mortality)...
Purpose Lenalidomide and rituximab (LR) are active agents in follicular lymphoma (FL). Combination regimens have not been previously assessed randomized studies. Patients Methods The Cancer Leukemia Group B (Alliance) 50401 trial is a phase II studying (375 mg/m 2 weekly for 4 weeks), lenalidomide (15 mg per day on days 1 to 21, followed by 7 of rest, cycle then 20 cycles 12), or LR. rituximab-alone arm was discontinued as result poor accrual. Eligibility included recurrent FL prior with...